Figure 2. Initiation Episodes of Disease-Modifying Therapies (DMTs) by Route of Administration in Adults (18 to 64 Years Old) With Multiple Sclerosis, 2001 Through 2020.

This figure displays the proportion of total new use episodes per year attributable to any DMT within each group among adults. Platform injectable DMTs include interferon β and glatiramer. Oral DMTs include dimethyl fumarate, diroximel fumarate, fingolimod, ozanimod, siponimod, teriflunomide, and cladribine. Infusion DMTs include alemtuzumab, natalizumab, and ocrelizumab. Off-label DMTs and newer injectable DMTs are not displayed in this graph due low usage in adults. A DMT claim was considered a new use episode if a patient had no claim for the same DMT within 1 year prior to the current DMT claim. Data for all routes of administration are shown in eTable 2 in Supplement 1.